Life Sciences VC gets €204M in its Biggest Fundraiser Ever

10/05/2016 - 2 minutes

MVM Capital has raised its fourth and largest funding round. It now has an additional €204M to invest in healthcare in the US and Europe.

mvm_capital_vc_healthcare_biotechWith offices in Boston and London, MVM Capital is an important VC in the healthcare sector – from biotechnology to medical devices.

Its biggest success story is perhaps Heptares, a UK Biotech researching applications of  G protein-coupled receptors (GPCRs) that was acquired by Sosei (Japan) – and went on to make billion euro deals with Pfizer and Allergan.

MVM has now closed its fourth healthcare fund (MVM IV), raising a total of €204M ($233M). This is a record for MVM, which has so far raised over €600M in its four funds.

MVM intends to spend their new funds mainly in a medical companies from the US and Europe.

It will consider all stages of development, as well as a range of sectors – from new therapeutics to medical devices and healthcare bioinformatics.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member